Diabetes
Applied Evidence
Choosing Wisely: 10 practices to stop—or adopt—to reduce overuse in health care
The evidence-based recommendations presented here, made by the AAFP and other societies, can help you to avoid unnecessary testing and...
Conference Coverage
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
From the Journals
PPIs associated with diabetes risk, but questions remain
Researchers call for blood glucose testing and diabetes surveillance in long-term PPI users, but causal evidence is weak.
Conference Coverage
Time to screen for liver disease in type 2 diabetes?
Questions remain on whether or not liver surveillance should be routine in people with type 2 diabetes.
Conference Coverage
Dapagliflozin’s CKD performance sends heart failure messages
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians...
Conference Coverage
British protocol allows insulin-treated pilots to fly safely
In a large study of commercial and private pilots with diabetes who followed strict rules, 98% of glucose levels were in target range and no pilot...
Guidelines
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
SGLT2 inhibitors and GLP-1 receptor agonists should be considered in people with type 2 diabetes and chronic kidney disease to protect against...
Pearl of the Month
Geriatric patients: My three rules for them
“Keeping moving” is probably the most important thing a patient can do for their health.
Conference Coverage
Higher glycemic time in range may benefit T2D patients
A post hoc analysis linked greater blood-glucose time in range with fewer hypoglycemic, microvascular, and major adverse cardiac events in T2D...
Conference Coverage
Exercise cuts diabetes death risk by a third in two studies
Results of two new studies provide further evidence that exercise reduces all-cause and cardiovascular mortality in those with type 2 diabetes.
Conference Coverage
DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
Until now, SGLT2 inhibitors were for patients with an eGFR of at least 30 mL/min per m2. New evidence moves the threshold down to 25....